No­var­tis may still be grap­pling with Kym­ri­ah sales, but his­toric CAR-T promise still shines through 5-year da­ta

Five years af­ter No­var­tis made his­to­ry with the ap­proval of the first CAR-T, Kym­ri­ah, we’re get­ting a clear­er pic­ture of just how im­por­tant the ad­vance was for some pa­tients.

The phar­ma gi­ant may still be hav­ing trou­ble man­u­fac­tur­ing the treat­ment or reach­ing long-cher­ished goals of block­buster rev­enue, but a new study shows that its pos­i­tive ef­fects have good odds of ex­tend­ing out for years. And for many, it’s look­ing cu­ra­tive.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.